Anteris Technologies Global Corp
NASDAQ:AVR
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
A
|
Anteris Technologies Global Corp
NASDAQ:AVR
|
544.5m USD |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
183.1B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
169.7B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
128.4B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
110.6B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
103B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.9B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
41.4B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
46B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
43.9B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
32.9B USD |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Anteris Technologies Global Corp
Glance View
Anteris Technologies Global Corp is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Eagan, Minnesota and currently employs 138 full-time employees. The company went IPO on 2024-12-13. Anteris Technologies Global Corp. is a structural heart company engaged in discovering, developing and commercializing medical devices designed to improve the quality of life for patients with aortic stenosis. The company is engaged in the research and development of its biomimetic technology (ADAPT, DurAVR Transcatheter Heart Valve (THV), ComASUR Transfemoral Delivery System) to address unmet medical needs in the treatment of aortic stenosis. The DurAVR THV, with its single piece, native-shaped biomimetic design is built to mimic the performance of a healthy aortic valve and to restore normal laminar (smooth) blood flow. This class of technology can be used to treat new aortic stenosis patients and to treat aortic stenosis patients with failed valves (valve-in-valve). ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. ComASUR is its balloon-expandable delivery system.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Anteris Technologies Global Corp is 70.3%, which is above its 3-year median of 59.7%.
Over the last 1 years, Anteris Technologies Global Corp’s Gross Margin has increased from 46.8% to 70.3%. During this period, it reached a low of 46.8% on Dec 1, 2024 and a high of 70.3% on Jan 31, 2026.
